Advances of using microfluidic chips for research and diagnosis of pulmonary inflammatory diseases.
- Author:
Taoran XIA
1
;
Wei ZOU
2
;
Jing LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: SARS-CoV-2; inflammatory diseases; lung diseases; lung-on-a-chip; microfluidic chip; pneumonia
- MeSH: Animals; Drug Evaluation, Preclinical; Humans; Lung; Microfluidic Analytical Techniques; Microfluidics
- From: Chinese Journal of Biotechnology 2021;37(11):3905-3914
- CountryChina
- Language:Chinese
- Abstract: Microfluidic chip technology integrates the sample preparation, reaction, separation and detection on a chip. It consists a network of microchannels, which controls the whole system through fluid. With the advantages of portability, high throughput, and the ability to simulate the microenvironment in vivo, it has a broad application prospect in the research of disease diagnosis, pathogenesis and drug screening. Pulmonary inflammatory disease is a common disease usually caused by bacterial, viral and fungal infections. Early pneumonia is often difficult to diagnose due to lack of obvious respiratory symptoms or the symptoms are mostly atypical, but the disease progresses rapidly. Recently, microfluidic chip technology has been increasingly used to the study of pulmonary inflammatory diseases. In particular, it has been used to develop a "lung-on-a-chip" model, which can reproduce the key structure, function and mechanical properties of human alveolar capillary interface (i.e., the basic functional unit of a living lung), and well simulate the alveoli in vitro. Compared with the cell and animal models, this multifunctional micro experimental platform has great advantages. This article summarizes the advances of using microfluidic chips for the research and diagnosis of pulmonary inflammatory diseases, with the aim to provide new ideas for researchers in this area.
